Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial
Cantargia AB today announced that the Pancreatic Cancer Action Network’s (PanCAN) Precision Promise[SM] phase 2/3 clinical trial, carried out at leading clinical US centers, plans to include nadunolimab in combination with chemotherapy as first-line experimental therapy in metastatic pancreatic cancer (PDAC). The trial utilizes a Bayesian platform designed by PanCAN in collaboration with the US Food and Drug Administration (FDA) to provide a basis for marketing approval of therapies in PDAC. The primary endpoint for the trial is overall survival. PanCAN’s plan is to submit a Pre-IND